People with higher body fat — as measured by body mass index, or BMI — have a lower risk of developing hypoparathyroidism following total thyroidectomy, a surgery that completely removes the thyroid glands, a new study reports. Besides body fat, levels of parathyroid hormone (PTH) before surgery and a…
The European Commission has approved palopegteriparatide, also known as TransCon PTH, to treat adults with chronic hypoparathyroidism. Ascendis Pharma, the therapy’s developer, will market it in the European Union under the brand name Yorvipath, and expects the therapy’s commercial launch to begin in Germany next month. An…
Use of Natpara (recombinant human parathyroid hormone) during early pregnancy and breastfeeding did not lead to significant adverse events for a woman with hypoparathyroidism or her two children, according to a recent case report from the U.S. The therapy’s safe use during pregnancy or while breastfeeding has not…
The experimental therapy TransCon PTH was effective at controlling hypoparathyroidism caused by neck surgery for most patients in the PaTHway clinical trial, according to data presented at the American Thyroid Association (ATA) annual meeting by its developer Ascendis Pharma. “We are pleased to share with thyroid surgeons…
People with hypoparathyroidism experience worse quality of life, with women showing a higher burden of disease than men, according to a recent survey in Germany. In addition, patients who’ve had the disease longer report a lower burden of their symptoms. “Investigations on potential coping strategies might give an explanation…
Hypoparathyroidism may play a role in serious health complications that require hospitalization for people with the disorder, but is rarely the direct cause of such problems, an Austrian study shows. Findings indicate the most common causes of serious health issues among people with chronic (ongoing) hypoparathyroidism are related to…
TransCon PTH treatment continues to show benefits for up to a year in people with hypoparathyroidism, helping them achieve normal blood calcium levels and reducing the need for conventional therapy. That’s according to new data from PATHway (NCT04701203), a Phase 3 clinical trial wherein Ascendis Pharma…
A natural history study of hypoparathyroidism taking place at Columbia University Irving Medical Center in New York has started to enroll adult patients. The study, called SHINE (NCT05793853), is recruiting an estimated 94 people, ages 18 and older, with any hypoparathyroidism subtype and undergoing any type of treatment…
Ascendis Pharma will request to meet with the U.S. Food and Drug Administration (FDA) in an effort to gain approval of TransCon PTH, its experimental hormone replacement therapy for hypoparathyroidism. “Based on our clinical experience with TransCon PTH to date, we have seen the improvement in the…
Using near-infrared autofluorescence (NIRAF) to protect the parathyroid glands during thyroid surgery did not significantly lower the risk of hypoparathyroidism as a surgical complication, a study with experienced thyroid surgeons reported. Although there were fewer hypoparathyroidism cases with NIRAF three months after surgery, differences  were not statistically significant when compared…
Get regular updates to your inbox.
